Does spironolactone reduce the risk of urinary tract cancers in hypertensive patients?
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- January 2017
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- 1116 Medical Physiology (FoR)
- Angiotensin-Converting Enzyme Inhibitors (MeSH)
- Cardiovascular System & Hematology (Science Metrix)
- Case-Control Studies (MeSH)
- Humans (MeSH)
- Hypertension (MeSH)
- Mineralocorticoid Receptor Antagonists (MeSH)
- Odds Ratio (MeSH)
- Retrospective Studies (MeSH)
- Risk (MeSH)
- Spironolactone (MeSH)
- Urologic Neoplasms (MeSH)
published in
- Journal of Hypertension Journal